Colorectal cancer in 2014: Progress in defining first-line and maintenance therapies

Joleen M. Hubbard; Axel Grothey

doi:10.1038/nrclinonc.2014.233

Colorectal cancer in 2014: Progress in defining first-line and maintenance therapies

Joleen M. Hubbard, Axel Grothey

Medical Oncology

Research output: Contribution to journal › Short survey › peer-review

25 Scopus citations

Abstract

The results of several clinical trials in metastatic colorectal cancer presented in 2014 will influence clinical practice. These findings include definitive data from phase III trials comparing bevacizumab and cetuximab-based therapy in the first-line, studies elucidating the value of maintenance therapy after induction treatment, and data on new agents in this disease.

Original language	English (US)
Pages (from-to)	73-74
Number of pages	2
Journal	Nature Reviews Clinical Oncology
Volume	12
Issue number	2
DOIs	https://doi.org/10.1038/nrclinonc.2014.233
State	Published - Feb 17 2015

ASJC Scopus subject areas

Oncology

Access to Document

10.1038/nrclinonc.2014.233

Cite this

@article{b4ef6fad683f43b7a0680524757c80dd,

title = "Colorectal cancer in 2014: Progress in defining first-line and maintenance therapies",

abstract = "The results of several clinical trials in metastatic colorectal cancer presented in 2014 will influence clinical practice. These findings include definitive data from phase III trials comparing bevacizumab and cetuximab-based therapy in the first-line, studies elucidating the value of maintenance therapy after induction treatment, and data on new agents in this disease.",

author = "Hubbard, {Joleen M.} and Axel Grothey",

year = "2015",

month = feb,

day = "17",

doi = "10.1038/nrclinonc.2014.233",

language = "English (US)",

volume = "12",

pages = "73--74",

journal = "Nature Reviews Clinical Oncology",

issn = "1759-4774",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Colorectal cancer in 2014

T2 - Progress in defining first-line and maintenance therapies

AU - Hubbard, Joleen M.

AU - Grothey, Axel

PY - 2015/2/17

Y1 - 2015/2/17

N2 - The results of several clinical trials in metastatic colorectal cancer presented in 2014 will influence clinical practice. These findings include definitive data from phase III trials comparing bevacizumab and cetuximab-based therapy in the first-line, studies elucidating the value of maintenance therapy after induction treatment, and data on new agents in this disease.

AB - The results of several clinical trials in metastatic colorectal cancer presented in 2014 will influence clinical practice. These findings include definitive data from phase III trials comparing bevacizumab and cetuximab-based therapy in the first-line, studies elucidating the value of maintenance therapy after induction treatment, and data on new agents in this disease.

UR - http://www.scopus.com/inward/record.url?scp=84923202077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923202077&partnerID=8YFLogxK

U2 - 10.1038/nrclinonc.2014.233

DO - 10.1038/nrclinonc.2014.233

M3 - Short survey

C2 - 25560533

AN - SCOPUS:84923202077

SN - 1759-4774

VL - 12

SP - 73

EP - 74

JO - Nature Reviews Clinical Oncology

JF - Nature Reviews Clinical Oncology

IS - 2

ER -

Colorectal cancer in 2014: Progress in defining first-line and maintenance therapies

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this